Oxford-AstraZeneca Vaccine `Much Easier to Distribute': Lancet Editor
Nov.19 -- Richard Horton, editor of The Lancet medical journal, comments on a study which showed that a Covid-19 vaccine being developed by the University of Oxford and AstraZeneca Plc produced a strong immune responses in older adults. "This is a very important step," Horton said in an interview on "Bloomberg Surveillance."
Видео Oxford-AstraZeneca Vaccine `Much Easier to Distribute': Lancet Editor канала Bloomberg Markets and Finance
Видео Oxford-AstraZeneca Vaccine `Much Easier to Distribute': Lancet Editor канала Bloomberg Markets and Finance
Показать
Комментарии отсутствуют
Информация о видео
19 ноября 2020 г. 14:45:30
00:02:03
Другие видео канала
Key researcher in AstraZeneca's Oxford vaccine breaks down trials data
Oxford University announces promising COVID clinical trial news l GMA
Vaccine against COVID-19: When will we bring the pandemic under control? | To the Point
Oxford, AstraZeneca expect COVID-19 vaccine to be ready before end-2020
How not to take things personally? | Frederik Imbo | TEDxMechelen
Bill Gates - COVID Vaccines, Climate Change & A New Podcast | The Daily Social Distancing Show
President Obama is Scared of Sasha and Roasts Donald Trump
What Is An mRNA Coronavirus Vaccine?
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at #HTLS2020
Rudy's Elite Strike Force Continues To Fail Spectacularly On Behalf Of Their Client, The President
Coronavirus in the US: What went wrong in the world’s largest economy? | COVID-19 Special
Coronavirus Update 117: Moderna vs. Pfizer COVID 19 Vaccine (mRNA vaccines)
Exciting New COVID Vaccine Trial Participant Says He Experienced 'No Issues' | Good Morning Britain
Moderna CEO on its 94.5% effective Covid-19 vaccine: We hope to get it to market soon
Vaccine, looking very good
Vaccines | Everything you need to know about the Oxford Vaccine
Oxford/AstraZeneca vaccine shows immune response in Phase 2 trial
Oxford Study Confirms Astra Vaccine Response in Older Adults
Jim Cramer breaks down how money managers are investing to close out 2020
Pfizer Applies For emergency Use Of Covid Vaccine Amid Testing Bottleneck: CNBC After Hours